Joe Duarte

Dr. Joe Duarte is Chief Investment Strategist and Editor of Profit Catalyst Alert and Weekly Cash Machine.  He has been a professional investor and independent analyst since 1990.  He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.  

Analyst Articles

This could be the final boarding call for buyers of Ambarella Inc. (Nasdaq: AMBA), a global leader in high-speed video chip technology, as the stock is approaching the top of our recommended buy range of $57 and looks ready to make its way toward the $60-plus area. Turnaround ProceedsI like Ambarella’s… Read More

It’s time to take profits on the McKesson January 19, 2018 195 LEAPS Call option (MCK_011918C195) after a major gain.  I recommended its purchase on May 26, 2016 and the long term option gained 43.9% as of the close of trading on July 14, based on the entry price of… Read More

Shares of The WhiteWave Foods Company (WWAV), a leader in organic and non-GMO food products, are trading significantly higher this morning on news that it received a $12.5 billion all-cash buyout offer from France’s Danone Foods, valuing shares of WhiteWave at $56.25, an 18% premium over its closing price on… Read More

Emergent BioSolutions (NYSE: EBS), a biotech company specializing in vaccines and bioterrorism related products, lost more than 25 percent of its value in one trading day on June 22nd.  Details on why this happened and what the future would bring were sketchy at first but are slowly becoming available.  Only… Read More

[from the 06/27/2016 edition of Breakthrough Tech Weekly]I found two stocks in our portfolio that are likely to face some headwinds due to Brexit related issues, Amgen (AMGN) and Bio-rad (BIO), so I recommend their immediate sales.Amgen is especially vulnerable, being a member of the Nasdaq 100 Index,… Read More

Global stock markets crashed and burned last week after the U.K. voted to leave the European Union, and it is not without reason to expect further losses over the next few days and weeks. Already the situation has become fluid with evidence of potential backtracking and softening of the rhetoric,… Read More